1
|
Vermillion Maier ML, Siddens LK, Pennington JM, Uesugi SL, Tilton SC, Vertel EA, Anderson KA, Tidwell LG, Ognibene TJ, Turteltaub KW, Smith JN, Williams DE. Benzo[a]pyrene toxicokinetics in humans following dietary supplementation with 3,3'-diindolylmethane (DIM) or Brussels sprouts. Toxicol Appl Pharmacol 2023; 460:116377. [PMID: 36642108 PMCID: PMC9946811 DOI: 10.1016/j.taap.2023.116377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Revised: 01/05/2023] [Accepted: 01/09/2023] [Indexed: 01/15/2023]
Abstract
Utilizing the atto-zeptomole sensitivity of UPLC-accelerator mass spectrometry (UPLC-AMS), we previously demonstrated significant first-pass metabolism following escalating (25-250 ng) oral micro-dosing in humans of [14C]-benzo[a]pyrene ([14C]-BaP). The present study examines the potential for supplementation with Brussels sprouts (BS) or 3,3'-diindolylmethane (DIM) to alter plasma levels of [14C]-BaP and metabolites over a 48-h period following micro-dosing with 50 ng (5.4 nCi) [14C]-BaP. Volunteers were dosed with [14C]-BaP following fourteen days on a cruciferous vegetable restricted diet, or the same diet supplemented for seven days with 50 g of BS or 300 mg of BR-DIM® prior to dosing. BS or DIM reduced total [14C] recovered from plasma by 56-67% relative to non-intervention. Dietary supplementation with DIM markedly increased Tmax and reduced Cmax for [14C]-BaP indicative of slower absorption. Both dietary treatments significantly reduced Cmax values of four downstream BaP metabolites, consistent with delaying BaP absorption. Dietary treatments also appeared to reduce the T1/2 and the plasma AUC(0,∞) for Unknown Metabolite C, indicating some effect in accelerating clearance of this metabolite. Toxicokinetic constants for other metabolites followed the pattern for [14C]-BaP (metabolite profiles remained relatively consistent) and non-compartmental analysis did not indicate other significant alterations. Significant amounts of metabolites in plasma were at the bay region of [14C]-BaP irrespective of treatment. Although the number of subjects and large interindividual variation are limitations of this study, it represents the first human trial showing dietary intervention altering toxicokinetics of a defined dose of a known human carcinogen.
Collapse
Affiliation(s)
- Monica L Vermillion Maier
- Linus Pauling Institute, Oregon State University, Corvallis, OR 97331, USA; Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR 97331, USA; Department of Environmental and Molecular Toxicology, ALS 1007, Oregon State University, Corvallis, OR 97331, USA.
| | - Lisbeth K Siddens
- Linus Pauling Institute, Oregon State University, Corvallis, OR 97331, USA; Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR 97331, USA.
| | - Jamie M Pennington
- Linus Pauling Institute, Oregon State University, Corvallis, OR 97331, USA; Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR 97331, USA.
| | - Sandra L Uesugi
- Linus Pauling Institute, Oregon State University, Corvallis, OR 97331, USA.
| | - Susan C Tilton
- Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR 97331, USA; NIEHS Superfund Research Program, Oregon State University, Corvallis, OR 97331, USA.
| | - Emily A Vertel
- Linus Pauling Institute, Oregon State University, Corvallis, OR 97331, USA; Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR 97331, USA.
| | - Kim A Anderson
- Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR 97331, USA; NIEHS Superfund Research Program, Oregon State University, Corvallis, OR 97331, USA.
| | - Lane G Tidwell
- Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR 97331, USA.
| | - Ted J Ognibene
- Center for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
| | - Kenneth W Turteltaub
- Center for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA; Biology and Biotechnology Research Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
| | - Jordan N Smith
- NIEHS Superfund Research Program, Oregon State University, Corvallis, OR 97331, USA; Chemical Biology and Exposure Science, Pacific Northwest National Laboratory, Richland, WA 99354, USA.
| | - David E Williams
- Linus Pauling Institute, Oregon State University, Corvallis, OR 97331, USA; Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR 97331, USA; NIEHS Superfund Research Program, Oregon State University, Corvallis, OR 97331, USA.
| |
Collapse
|
2
|
Singh RSP, Dowty ME, Salganik M, Brodfuehrer JI, Walker GS, Sharma R, Beebe JS, Danto SI. A Phase 1 Study to Assess Mass Balance and Absolute Bioavailability of Zimlovisertib in Healthy Male Participants Using a 14 C-Microtracer Approach. Clin Pharmacol Drug Dev 2022; 11:815-825. [PMID: 35506501 PMCID: PMC9322294 DOI: 10.1002/cpdd.1109] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2021] [Accepted: 04/04/2022] [Indexed: 12/03/2022]
Abstract
Zimlovisertib (PF‐06650833) is a selective, reversible inhibitor of interleukin‐1 receptor‐associated kinase 4 (IRAK4) with anti‐inflammatory effects. This phase 1, open‐label, fixed‐sequence, two‐period, single‐dose study aimed to evaluate the mass balance and excretion rate of zimlovisertib in healthy male participants using a 14C‐microtracer approach. All six participants received 300 mg 14C‐zimlovisertib with lower radioactivity per mass unit orally in Period A, then unlabeled zimlovisertib 300 mg orally and 14C‐zimlovisertib 135 μg intravenously (IV) in Period B. Study objectives included extent and rate of excretion of 14C‐zimlovisertib, pharmacokinetics, and safety and tolerability of oral and IV zimlovisertib. Total radioactivity recovered in urine and feces was 82.4% ± 6.8% (urine 23.1% ± 12.3%, feces 59.3% ± 9.7%) in Period A. Zimlovisertib was absorbed rapidly following oral administration, with the fraction absorbed estimated to be 44%. Absolute oral bioavailability of the 300‐mg dose was 17.4% (90% confidence interval 14.1%, 21.5%) using the dose‐normalized area under the concentration–time curve from time 0 to infinity. There were no deaths, serious adverse events (AEs), severe AEs, discontinuations or dose reductions due to AEs, and no clinically significant laboratory abnormalities. These results demonstrate that zimlovisertib had low absolute oral bioavailability and low absorption (<50%).
Collapse
|
3
|
Stewart BJ, Ognibene TJ. Parallel Accelerator and Molecular Mass Spectrometry Measurement of Carbon-14-Labeled Analytes. Methods Mol Biol 2022; 2349:1-10. [PMID: 34718988 PMCID: PMC10868718 DOI: 10.1007/978-1-0716-1585-0_1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Parallel accelerator and molecular mass spectrometry (PAMMS) is a powerful analytical technique capable of simultaneous quantitation of carbon-14 tracer and structural characterization of 14C-labeled biomolecules. Here we describe the use of PAMMS for the analysis of biological molecules separated by high-performance liquid chromatography. This protocol is intended to serve as a guide for researchers who need to perform PAMMS experiments using instrumentation available at resource centers such as the National User Resource for Biological Accelerator Mass Spectrometry at Lawrence Livermore National Laboratory.
Collapse
Affiliation(s)
- Benjamin J Stewart
- Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.
| | - Ted J Ognibene
- Center for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory, Livermore, CA, USA
| |
Collapse
|
4
|
Cai H, Scott EN, Britton RG, Parrott E, Ognibene TJ, Malfatti M, Khan M, Steward WP, Brown K. Distribution and metabolism of [14C]-resveratrol in human prostate tissue after oral administration of a "dietary-achievable" or "pharmacological" dose: what are the implications for anticancer activity? Am J Clin Nutr 2021; 113:1115-1125. [PMID: 33675348 PMCID: PMC8106746 DOI: 10.1093/ajcn/nqaa414] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2020] [Accepted: 12/08/2020] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND The dietary polyphenol resveratrol prevents various malignancies in preclinical models, including prostate cancer. Despite attempts to translate findings to humans, gaps remain in understanding pharmacokinetic-pharmacodynamic relations and how tissue concentrations affect efficacy. Such information is necessary for dose selection and is particularly important given the low bioavailability of resveratrol. OBJECTIVES This study aimed to determine concentrations of resveratrol in prostate tissue of men after a dietary-achievable (5 mg) or pharmacological (1 g) dose. We then examined whether clinically relevant concentrations of resveratrol/its metabolites had direct anticancer activity in prostate cell lines. METHODS A window trial was performed in which patients were allocated to 5 mg or 1 g resveratrol daily, or no intervention, before prostate biopsy. Patients (10/group) ingested resveratrol capsules for 7-14 d before biopsy, with the last dose [14C]-labeled, allowing detection of resveratrol species in prostate tissue using accelerator MS. Cellular uptake and antiproliferative properties of resveratrol/metabolites were assessed in cancer and nonmalignant cell cultures using HPLC with UV detection and cell counting, respectively. RESULTS [14C]-Resveratrol species were detectable in prostate tissue of all patients analyzed, with mean ± SD concentrations of 0.08 ± 0.04 compared with 22.1 ± 8.2 pmol/mg tissue for the 5 mg and the 1 g dose, respectively. However, total [14C]-resveratrol equivalents in prostate were lower than we previously reported in plasma and colorectum after identical doses. Furthermore, resveratrol was undetectable in prostate tissue; instead, sulfate and glucuronide metabolites dominated. Although resveratrol reduced prostate cell numbers in vitro over 7 d, the concentrations required (≥10 µM) exceeded the plasma maximum concentration. Resveratrol mono-sulfates and glucuronides failed to consistently inhibit cell growth, partly due to poor cellular uptake. CONCLUSIONS Low tissue concentrations of resveratrol species, coupled with weak antiproliferative activity of its conjugates, suggest daily doses of ≤1 g may not have direct effects on human prostate.This trial was registered at clinicaltrialsregister.eu as EudraCT 2007-002131-91.
Collapse
Affiliation(s)
- Hong Cai
- Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom
| | - Edwina N Scott
- Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom
| | - Robert G Britton
- Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom
| | - Emma Parrott
- Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom
| | - Ted J Ognibene
- Lawrence Livermore National Laboratory, Livermore, CA, USA
| | | | - Masood Khan
- University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
| | - William P Steward
- Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom
| | | |
Collapse
|
5
|
Madeen E, Siddens LK, Uesugi S, McQuistan T, Corley RA, Smith J, Waters KM, Tilton SC, Anderson KA, Ognibene T, Turteltaub K, Williams DE. Toxicokinetics of benzo[a]pyrene in humans: Extensive metabolism as determined by UPLC-accelerator mass spectrometry following oral micro-dosing. Toxicol Appl Pharmacol 2018; 364:97-105. [PMID: 30582946 DOI: 10.1016/j.taap.2018.12.010] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2018] [Revised: 12/13/2018] [Accepted: 12/17/2018] [Indexed: 10/27/2022]
Abstract
Benzo[a]pyrene (BaP), is a known human carcinogen (International Agency for Research on Cancer (IARC) class 1). The remarkable sensitivity (zepto-attomole 14C in biological samples) of accelerator mass spectrometry (AMS) makes possible, with de minimus risk, pharmacokinetic (PK) analysis following [14C]-BaP micro-dosing of humans. A 46 ng (5 nCi) dose was given thrice to 5 volunteers with minimum 2 weeks between dosing and plasma collected over 72 h. [14C]-BaPeq PK analysis gave plasma Tmax and Cmax values of 1.25 h and 29-82 fg/mL, respectively. PK parameters were assessed by non- compartment and compartment models. Intervals between dosing ranged from 20 to 420 days and had little impact on intra-individual variation. DNA, extracted from peripheral blood mononuclear cells (PBMCs) of 4 volunteers, showed measurable levels (LOD ~ 0.5 adducts/1011 nucleotides) in two individuals 2-3 h post-dose, approximately three orders of magnitude lower than smokers or occupationally-exposed individuals. Little or no DNA binding was detectable at 48-72 h. In volunteers the allelic variants CYP1B1*1/*⁎1, *1/*3 or *3/*3 and GSTM1*0/0 or *1 had no impact on [14C]-BaPeq PK or DNA adduction with this very limited sample. Plasma metabolites over 72 h from two individuals (one CYP1B1*1/*1 and one CYP1B1*3/*3) were analyzed by UPLC-AMS. In both individuals, parent [14C]-BaP was a minor constituent even at the earliest time points and metabolite profiles markedly distinct. AMS, coupled with UPLC, could be used in humans to enhance the accuracy of pharmacokinetics, toxicokinetics and risk assessment of environmental carcinogens.
Collapse
Affiliation(s)
- Erin Madeen
- Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA; NIEHS Superfund Research Program, Oregon State University, Corvallis, OR, USA
| | - Lisbeth K Siddens
- Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA; NIEHS Superfund Research Program, Oregon State University, Corvallis, OR, USA; Linus Pauling Institute, Oregon State University, Corvallis, OR, USA
| | - Sandra Uesugi
- Linus Pauling Institute, Oregon State University, Corvallis, OR, USA
| | | | - Richard A Corley
- NIEHS Superfund Research Program, Oregon State University, Corvallis, OR, USA; Chemical Biology and Exposure Science, Pacific Northwest National Laboratory, Richland, WA, USA
| | - Jordan Smith
- NIEHS Superfund Research Program, Oregon State University, Corvallis, OR, USA; Chemical Biology and Exposure Science, Pacific Northwest National Laboratory, Richland, WA, USA
| | - Katrina M Waters
- NIEHS Superfund Research Program, Oregon State University, Corvallis, OR, USA; Chemical Biology and Exposure Science, Pacific Northwest National Laboratory, Richland, WA, USA
| | - Susan C Tilton
- Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA; NIEHS Superfund Research Program, Oregon State University, Corvallis, OR, USA
| | - Kim A Anderson
- Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA; NIEHS Superfund Research Program, Oregon State University, Corvallis, OR, USA
| | - Ted Ognibene
- Center for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory, Livermore, CA, USA
| | - Kenneth Turteltaub
- Center for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory, Livermore, CA, USA; Biology and Biotechnology Research Division, Lawrence Livermore National Laboratory, Livermore, CA, USA
| | - David E Williams
- Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA; NIEHS Superfund Research Program, Oregon State University, Corvallis, OR, USA; Linus Pauling Institute, Oregon State University, Corvallis, OR, USA.
| |
Collapse
|
6
|
Inorganic Mass Spectrometry. Mass Spectrom (Tokyo) 2017. [DOI: 10.1007/978-3-319-54398-7_15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
7
|
Enright HA, Malfatti MA, Zimmermann M, Ognibene T, Henderson P, Turteltaub KW. Use of Accelerator Mass Spectrometry in Human Health and Molecular Toxicology. Chem Res Toxicol 2016; 29:1976-1986. [PMID: 27726383 PMCID: PMC5203773 DOI: 10.1021/acs.chemrestox.6b00234] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Accelerator mass spectrometry (AMS) has been adopted as a powerful bioanalytical method for human studies in the areas of pharmacology and toxicology. The exquisite sensitivity (10-18 mol) of AMS has facilitated studies of toxins and drugs at environmentally and physiologically relevant concentrations in humans. Such studies include risk assessment of environmental toxicants, drug candidate selection, absolute bioavailability determination, and more recently, assessment of drug-target binding as a biomarker of response to chemotherapy. Combining AMS with complementary capabilities such as high performance liquid chromatography (HPLC) can maximize data within a single experiment and provide additional insight when assessing drugs and toxins, such as metabolic profiling. Recent advances in the AMS technology at Lawrence Livermore National Laboratory have allowed for direct coupling of AMS with complementary capabilities such as HPLC via a liquid sample moving wire interface, offering greater sensitivity compared to that of graphite-based analysis, therefore enabling the use of lower 14C and chemical doses, which are imperative for clinical testing. The aim of this review is to highlight the recent efforts in human studies using AMS, including technological advancements and discussion of the continued promise of AMS for innovative clinical based research.
Collapse
Affiliation(s)
- Heather A. Enright
- Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA USA
| | - Michael A. Malfatti
- Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA USA
| | - Maike Zimmermann
- Department of Internal Medicine, Division of Hematology and Oncology, UC Davis Medical Center, Sacramento, CA USA
- Accelerated Medical Diagnostics Incorporated, Berkeley, CA USA
| | - Ted Ognibene
- Center for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory, Livermore, CA USA
| | - Paul Henderson
- Department of Internal Medicine, Division of Hematology and Oncology, UC Davis Medical Center, Sacramento, CA USA
- Accelerated Medical Diagnostics Incorporated, Berkeley, CA USA
| | - Kenneth W. Turteltaub
- Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA USA
| |
Collapse
|
8
|
Cai H, Scott E, Kholghi A, Andreadi C, Rufini A, Karmokar A, Britton RG, Horner-Glister E, Greaves P, Jawad D, James M, Howells L, Ognibene T, Malfatti M, Goldring C, Kitteringham N, Walsh J, Viskaduraki M, West K, Miller A, Hemingway D, Steward WP, Gescher AJ, Brown K. Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice. Sci Transl Med 2016. [PMID: 26223300 DOI: 10.1126/scitranslmed.aaa7619] [Citation(s) in RCA: 120] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Resveratrol is widely promoted as a potential cancer chemopreventive agent, but a lack of information on the optimal dose prohibits rationally designed trials to assess efficacy. To challenge the assumption that "more is better," we compared the pharmacokinetics and activity of a dietary dose with an intake 200 times higher. The dose-response relationship for concentrations generated and the metabolite profile of [(14)C]-resveratrol in colorectal tissue of cancer patients helped us to define clinically achievable levels. In Apc(Min) mice (a model of colorectal carcinogenesis) that received a high-fat diet, the low resveratrol dose suppressed intestinal adenoma development more potently than did the higher dose. Efficacy correlated with activation of adenosine monophosphate-activated protein kinase (AMPK) and increased expression of the senescence marker p21. Nonlinear dose responses were observed for AMPK and mechanistic target of rapamycin (mTOR) signaling in mouse adenoma cells, culminating in autophagy and senescence. In human colorectal tissues exposed to low dietary concentrations of resveratrol ex vivo, we measured enhanced AMPK phosphorylation and autophagy. The expression of the cytoprotective NAD(P)H dehydrogenase, quinone 1 (NQO1) enzyme was also increased in tissues from cancer patients participating in our [(14)C]-resveratrol trial. These findings warrant a revision of developmental strategies for diet-derived agents designed to achieve cancer chemoprevention.
Collapse
Affiliation(s)
- Hong Cai
- Cancer Chemoprevention Group, Department of Cancer Studies, University of Leicester, Leicester LE2 7LX, UK
| | - Edwina Scott
- Cancer Chemoprevention Group, Department of Cancer Studies, University of Leicester, Leicester LE2 7LX, UK
| | - Abeer Kholghi
- Cancer Chemoprevention Group, Department of Cancer Studies, University of Leicester, Leicester LE2 7LX, UK
| | - Catherine Andreadi
- Cancer Chemoprevention Group, Department of Cancer Studies, University of Leicester, Leicester LE2 7LX, UK
| | - Alessandro Rufini
- Cancer Chemoprevention Group, Department of Cancer Studies, University of Leicester, Leicester LE2 7LX, UK
| | - Ankur Karmokar
- Cancer Chemoprevention Group, Department of Cancer Studies, University of Leicester, Leicester LE2 7LX, UK
| | - Robert G Britton
- Cancer Chemoprevention Group, Department of Cancer Studies, University of Leicester, Leicester LE2 7LX, UK
| | - Emma Horner-Glister
- Cancer Chemoprevention Group, Department of Cancer Studies, University of Leicester, Leicester LE2 7LX, UK
| | - Peter Greaves
- Cancer Chemoprevention Group, Department of Cancer Studies, University of Leicester, Leicester LE2 7LX, UK
| | - Dhafer Jawad
- Cancer Chemoprevention Group, Department of Cancer Studies, University of Leicester, Leicester LE2 7LX, UK
| | - Mark James
- Cancer Chemoprevention Group, Department of Cancer Studies, University of Leicester, Leicester LE2 7LX, UK
| | - Lynne Howells
- Cancer Chemoprevention Group, Department of Cancer Studies, University of Leicester, Leicester LE2 7LX, UK
| | - Ted Ognibene
- Lawrence Livermore National Laboratory, 7000 East Avenue, Livermore, CA 94551, USA
| | - Michael Malfatti
- Lawrence Livermore National Laboratory, 7000 East Avenue, Livermore, CA 94551, USA
| | - Christopher Goldring
- MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, University of Liverpool, Sherrington Building, Ashton Street, Liverpool L69 3GE, UK
| | - Neil Kitteringham
- MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, University of Liverpool, Sherrington Building, Ashton Street, Liverpool L69 3GE, UK
| | - Joanne Walsh
- MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, University of Liverpool, Sherrington Building, Ashton Street, Liverpool L69 3GE, UK
| | - Maria Viskaduraki
- Bioinformatics and Biostatistics Support Hub, University of Leicester, Maurice Shock Building, Leicester LE1 9HN, UK
| | - Kevin West
- University Hospitals of Leicester NHS Trust, Leicester LE1 5WW, UK
| | - Andrew Miller
- University Hospitals of Leicester NHS Trust, Leicester LE1 5WW, UK
| | - David Hemingway
- University Hospitals of Leicester NHS Trust, Leicester LE1 5WW, UK
| | - William P Steward
- Cancer Chemoprevention Group, Department of Cancer Studies, University of Leicester, Leicester LE2 7LX, UK
| | - Andreas J Gescher
- Cancer Chemoprevention Group, Department of Cancer Studies, University of Leicester, Leicester LE2 7LX, UK
| | - Karen Brown
- Cancer Chemoprevention Group, Department of Cancer Studies, University of Leicester, Leicester LE2 7LX, UK.
| |
Collapse
|
9
|
Madeen E, Corley RA, Crowell S, Turteltaub K, Ognibene T, Malfatti M, McQuistan T, Garrard M, Sudakin D, Williams DE. Human in Vivo Pharmacokinetics of [(14)C]Dibenzo[def,p]chrysene by Accelerator Mass Spectrometry Following Oral Microdosing. Chem Res Toxicol 2015; 28:126-34. [PMID: 25418912 PMCID: PMC4303324 DOI: 10.1021/tx5003996] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2014] [Indexed: 11/28/2022]
Abstract
Dibenzo(def,p)chrysene (DBC), (also known as dibenzo[a,l]pyrene), is a high molecular weight polycyclic aromatic hydrocarbon (PAH) found in the environment, including food, produced by the incomplete combustion of hydrocarbons. DBC, classified by IARC as a 2A probable human carcinogen, has a relative potency factor (RPF) in animal cancer models 30-fold higher than benzo[a]pyrene. No data are available describing the disposition of high molecular weight (>4 rings) PAHs in humans to compare to animal studies. Pharmacokinetics of DBC was determined in 3 female and 6 male human volunteers following oral microdosing (29 ng, 5 nCi) of [(14)C]-DBC. This study was made possible with highly sensitive accelerator mass spectrometry (AMS), capable of detecting [(14)C]-DBC equivalents in plasma and urine following a dose considered of de minimus risk to human health. Plasma and urine were collected over 72 h. The plasma Cmax was 68.8 ± 44.3 fg·mL(-1) with a Tmax of 2.25 ± 1.04 h. Elimination occurred in two distinct phases: a rapid (α)-phase, with a T1/2 of 5.8 ± 3.4 h and an apparent elimination rate constant (Kel) of 0.17 ± 0.12 fg·h(-1), followed by a slower (β)-phase, with a T1/2 of 41.3 ± 29.8 h and an apparent Kel of 0.03 ± 0.02 fg·h(-1). In spite of the high degree of hydrophobicity (log Kow of 7.4), DBC was eliminated rapidly in humans, as are most PAHs in animals, compared to other hydrophobic persistent organic pollutants such as, DDT, PCBs and TCDD. Preliminary examination utilizing a new UHPLC-AMS interface, suggests the presence of polar metabolites in plasma as early as 45 min following dosing. This is the first in vivo data set describing pharmacokinetics in humans of a high molecular weight PAH and should be a valuable addition to risk assessment paradigms.
Collapse
Affiliation(s)
- Erin Madeen
- Department of Environmental and Molecular Toxicology, Superfund Research
Center, Linus Pauling Institute, and Environmental Health Sciences Center, Oregon State University, Corvallis, Oregon 97331, United States
| | - Richard A. Corley
- Department of Environmental and Molecular Toxicology, Superfund Research
Center, Linus Pauling Institute, and Environmental Health Sciences Center, Oregon State University, Corvallis, Oregon 97331, United States
- Systems
Toxicology & Exposure Science, Pacific
Northwest National Laboratory, Richland, Washington 99354, United States
| | - Susan Crowell
- Department of Environmental and Molecular Toxicology, Superfund Research
Center, Linus Pauling Institute, and Environmental Health Sciences Center, Oregon State University, Corvallis, Oregon 97331, United States
- Systems
Toxicology & Exposure Science, Pacific
Northwest National Laboratory, Richland, Washington 99354, United States
| | - Kenneth Turteltaub
- Biology and
Biotechnology Research Division, and the Center for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory, Livermore, California 94550, United States
| | - Ted Ognibene
- Biology and
Biotechnology Research Division, and the Center for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory, Livermore, California 94550, United States
| | - Mike Malfatti
- Biology and
Biotechnology Research Division, and the Center for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory, Livermore, California 94550, United States
| | - Tammie
J. McQuistan
- Department of Environmental and Molecular Toxicology, Superfund Research
Center, Linus Pauling Institute, and Environmental Health Sciences Center, Oregon State University, Corvallis, Oregon 97331, United States
| | - Mary Garrard
- Department of Environmental and Molecular Toxicology, Superfund Research
Center, Linus Pauling Institute, and Environmental Health Sciences Center, Oregon State University, Corvallis, Oregon 97331, United States
| | - Dan Sudakin
- Department of Environmental and Molecular Toxicology, Superfund Research
Center, Linus Pauling Institute, and Environmental Health Sciences Center, Oregon State University, Corvallis, Oregon 97331, United States
| | - David E. Williams
- Department of Environmental and Molecular Toxicology, Superfund Research
Center, Linus Pauling Institute, and Environmental Health Sciences Center, Oregon State University, Corvallis, Oregon 97331, United States
| |
Collapse
|
10
|
Wang B, Jackson GS, Yokel RA, Grulke EA. Applying accelerator mass spectrometry for low-level detection of complex engineered nanoparticles in biological media. J Pharm Biomed Anal 2014; 97:81-7. [DOI: 10.1016/j.jpba.2014.04.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2014] [Revised: 03/28/2014] [Accepted: 04/02/2014] [Indexed: 10/25/2022]
|
11
|
Cadet J, Douki T, Ravanat JL, Wagner JR. Measurement of oxidatively generated base damage to nucleic acids in cells: facts and artifacts. ACTA ACUST UNITED AC 2012. [DOI: 10.1007/s12566-012-0029-6] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
12
|
Abstract
The detection and characterisation of DNA adducts can provide mechanistic information on mode of action for genotoxic chemicals and in this context is vital for human risk assessments. Adducts are measured extensively in biomonitoring studies to examine exposure to environmental, dietary, and occupational chemicals and as biomarkers of efficacy for cancer chemotherapeutic drugs and chemopreventive agents. Methods used for adduct analysis must possess a certain degree of specificity and be sufficiently sensitive to detect lesions in the model system under investigation. A variety of techniques have been established for this purpose, which are capable of detecting and quantifying adducts in DNA isolated from animal or human tissues, cells, and biofluids as well as naked DNA from in vitro studies. These can be grouped as those involving (32)P-post-labelling, mass spectrometry, physical detection methods, immunological assays and radiolabelled compounds. Each approach presents different advantages and limitations and the most appropriate method depends on the type of sample, level of damage, and nature of the investigation as well as practical considerations. In this chapter, the basic principles of the most commonly used quantitative methods are described and their strengths and weaknesses discussed.
Collapse
Affiliation(s)
- Karen Brown
- Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK.
| |
Collapse
|
13
|
|
14
|
Scott E, Steward WP, Gescher AJ, Brown K. Resveratrol in human cancer chemoprevention--choosing the 'right' dose. Mol Nutr Food Res 2011; 56:7-13. [PMID: 22218912 DOI: 10.1002/mnfr.201100400] [Citation(s) in RCA: 91] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2011] [Revised: 07/27/2011] [Accepted: 08/09/2011] [Indexed: 12/31/2022]
Abstract
There is now robust preclinical evidence to suggest that resveratrol possesses cancer chemopreventive properties. A series of clinical pilot studies has provided insights into its pharmacokinetics, and data on its human antineoplastic pharmacodynamics start to emerge. It is likely that resveratrol will be developed further in the clinic as a putative cancer chemopreventive agent. The question that remains unresolved is: What is the most suitable dose of resveratrol for effective cancer preventive intervention? Mechanistic studies in cells in vitro have almost invariably used concentrations of resveratrol in the 10(-5) to 10(-4) M range, which is much higher than those which can be achieved in the human biophase after consumption of doses up to 1 g. Many of the preclinical efficacy studies in rodent models of carcinogenesis have employed doses which are dramatically above those which can be ingested with the diet. New experimental paradigms need to be used to obtain information on pharmacological changes elicited by resveratrol when present at very low concentrations or when administered at dietary-relevant doses.
Collapse
Affiliation(s)
- Edwina Scott
- Cancer Biomarkers and Prevention Group, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK
| | | | | | | |
Collapse
|
15
|
Gao L, Li J, Kasserra C, Song Q, Arjomand A, Hesk D, Chowdhury SK. Precision and Accuracy in the Quantitative Analysis of Biological Samples by Accelerator Mass Spectrometry: Application in Microdose Absolute Bioavailability Studies. Anal Chem 2011; 83:5607-16. [DOI: 10.1021/ac2006284] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
| | | | | | - Qi Song
- Accium BioSciences, Inc., Seattle, Washington 98122, United States
| | - Ali Arjomand
- Accium BioSciences, Inc., Seattle, Washington 98122, United States
| | | | | |
Collapse
|
16
|
Kim SH, Chuang JC, Kelly PB, Clifford AJ. Carbon isotopes profiles of human whole blood, plasma, red blood cells, urine and feces for biological/biomedical 14C-accelerator mass spectrometry applications. Anal Chem 2011; 83:3312-8. [PMID: 21452856 DOI: 10.1021/ac103038s] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Radiocarbon ((14)C) is an ideal tracer for in vivo human ADME (absorption, distribution, metabolism, elimination) and PBPK (physiological-based pharmacokinetic) studies. Living plants peferentially incorporate atmospheric (14)CO(2) versus (13)CO(2) versus (12)CO(2), which result in unique signature. Furthermore, plants and the food chains they support also have unique carbon isotope signatures. Humans, at the top of the food chain, consequently acquire isotopic concentrations in the tissues and body fluids depending on their dietary habits. In preparation of ADME and PBPK studies, 12 healthy subjects were recruited. The human baseline (specific to each individual and their diet) total carbon (TC) and carbon isotope (13)C (δ(13)C) and (14)C (F(m)) were quantified in whole blood (WB), plasma, washed red blood cell (RBC), urine, and feces. TC (mg of C/100 μL) in WB, plasma, RBC, urine, and feces were 11.0, 4.37, 7.57, 0.53, and 1.90, respectively. TC in WB, RBC, and feces was higher in men over women, P < 0.05. Mean δ(13)C were ranked low to high as follows: feces < WB = plasma = RBC = urine, P < 0.0001. δ(13)C was not affected by gender. Our analytic method shifted δ(13)C by only ±1.0 ‰ ensuring our F(m) measurements were accurate and precise. Mean F(m) were ranked low to high as follows: plasma = urine < WB = RBC = feces, P < 0.05. F(m) in feces was higher for men over women, P < 0.05. Only in WB, (14)C levels (F(m)) and TC were correlated with one another (r = 0.746, P < 0.01). Considering the lag time to incorporate atmospheric (14)C into plant foods (vegetarian) and or then into animal foods (nonvegetarian), the measured F(m) of WB in our population (recruited April 2009) was 1.0468 ± 0.0022 (mean ± SD), and the F(m) of WB matched the (extrapolated) atmospheric F(m) of 1.0477 in 2008. This study is important in presenting a procedure to determine a baseline for a study group for human ADME and PBPK studies using (14)C as a tracer.
Collapse
Affiliation(s)
- Seung-Hyun Kim
- Department of Nutrition, University of California Davis, 95616, USA
| | | | | | | |
Collapse
|
17
|
Accelerator mass spectrometry-enabled studies: current status and future prospects. Bioanalysis 2011; 2:519-41. [PMID: 20440378 DOI: 10.4155/bio.09.188] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Accelerator mass spectrometry is a detection platform with exceptional sensitivity compared with other bioanalytical platforms. Accelerator mass spectrometry (AMS) is widely used in archeology for radiocarbon dating applications. Early exploration of the biological and pharmaceutical applications of AMS began in the early 1990s. AMS has since demonstrated unique problem-solving ability in nutrition science, toxicology and pharmacology. AMS has also enabled the development of new applications, such as Phase 0 microdosing. Recent development of AMS-enabled applications has transformed this novelty research instrument to a valuable tool within the pharmaceutical industry. Although there is now greater awareness of AMS technology, recognition and appreciation of the range of AMS-enabled applications is still lacking, including study-design strategies. This review aims to provide further insight into the wide range of AMS-enabled applications. Examples of studies conducted over the past two decades will be presented, as well as prospects for the future of AMS.
Collapse
|
18
|
Gross JH. Inorganic Mass Spectrometry. Mass Spectrom (Tokyo) 2011. [DOI: 10.1007/978-3-642-10711-5_15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
19
|
Stewart BJ, Navid A, Turteltaub KW, Bench G. Yeast dynamic metabolic flux measurement in nutrient-rich media by HPLC and accelerator mass spectrometry. Anal Chem 2010; 82:9812-7. [PMID: 21062031 DOI: 10.1021/ac102065f] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Metabolic flux, the flow of metabolites through networks of enzymes, represents the dynamic productive output of cells. Improved understanding of intracellular metabolic fluxes will enable targeted manipulation of metabolic pathways of medical and industrial importance to a greater degree than is currently possible. Flux balance analysis (FBA) is a constraint-based approach to modeling metabolic fluxes, but its utility is limited by a lack of experimental measurements. Incorporation of experimentally measured fluxes as system constraints will significantly improve the overall accuracy of FBA. We applied a novel, two-tiered approach in the yeast Saccharomyces cerevisiae to measure nutrient consumption rates (extracellular fluxes) and a targeted intracellular flux using a (14)C-labeled precursor with HPLC separation and flux quantitation by accelerator mass spectrometry (AMS). The use of AMS to trace the intracellular fate of (14)C-glutamine allowed the calculation of intracellular metabolic flux through this pathway, with glutathione as the metabolic end point. Measured flux values provided global constraints for the yeast FBA model which reduced model uncertainty by more than 20%, proving the importance of additional constraints in improving the accuracy of model predictions and demonstrating the use of AMS to measure intracellular metabolic fluxes. Our results highlight the need to use intracellular fluxes to constrain the models. We show that inclusion of just one such measurement alone can reduce the average variability of model predicted fluxes by 10%.
Collapse
Affiliation(s)
- Benjamin J Stewart
- Lawrence Livermore National Laboratory, Center for Accelerator Mass Spectrometry, 7000 East Avenue P.O. Box 808, L-397 Livermore, California 94551, USA.
| | | | | | | |
Collapse
|
20
|
Kirillova EN, Sheesley RJ, Andersson A, Gustafsson Ö. Natural Abundance 13C and 14C Analysis of Water-Soluble Organic Carbon in Atmospheric Aerosols. Anal Chem 2010; 82:7973-8. [DOI: 10.1021/ac1014436] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Elena N. Kirillova
- Department of Applied Environmental Science (ITM) and Bert Bolin Climate Research Centre, Stockholm University, Sweden, and Department of Environmental Science, Baylor University, Waco, Texas 76798
| | - Rebecca J. Sheesley
- Department of Applied Environmental Science (ITM) and Bert Bolin Climate Research Centre, Stockholm University, Sweden, and Department of Environmental Science, Baylor University, Waco, Texas 76798
| | - August Andersson
- Department of Applied Environmental Science (ITM) and Bert Bolin Climate Research Centre, Stockholm University, Sweden, and Department of Environmental Science, Baylor University, Waco, Texas 76798
| | - Örjan Gustafsson
- Department of Applied Environmental Science (ITM) and Bert Bolin Climate Research Centre, Stockholm University, Sweden, and Department of Environmental Science, Baylor University, Waco, Texas 76798
| |
Collapse
|
21
|
Boccard J, Veuthey JL, Rudaz S. Knowledge discovery in metabolomics: An overview of MS data handling. J Sep Sci 2010; 33:290-304. [DOI: 10.1002/jssc.200900609] [Citation(s) in RCA: 139] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
22
|
Jones GDD, Le Pla RC, Farmer PB. Phosphotriester adducts (PTEs): DNA's overlooked lesion. Mutagenesis 2009; 25:3-16. [DOI: 10.1093/mutage/gep038] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
23
|
Rubino FM, Pitton M, Di Fabio D, Colombi A. Toward an "omic" physiopathology of reactive chemicals: thirty years of mass spectrometric study of the protein adducts with endogenous and xenobiotic compounds. MASS SPECTROMETRY REVIEWS 2009; 28:725-84. [PMID: 19127566 DOI: 10.1002/mas.20207] [Citation(s) in RCA: 84] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
Cancer and degenerative diseases are major causes of morbidity and death, derived from the permanent modification of key biopolymers such as DNA and regulatory proteins by usually smaller, reactive molecules, present in the environment or generated from endogenous and xenobiotic components by the body's own biochemical mechanisms (molecular adducts). In particular, protein adducts with organic electrophiles have been studied for more than 30 [see, e.g., Calleman et al., 1978] years essentially for three purposes: (a) as passive monitors of the mean level of individual exposure to specific chemicals, either endogenously present in the human body or to which the subject is exposed through food or environmental contamination; (b) as quantitative indicators of the mean extent of the individual metabolic processing which converts a non-reactive chemical substance into its toxic products able to damage DNA (en route to cancer induction through genotoxic mechanisms) or key proteins (as in the case of several drugs, pesticides or otherwise biologically active substances); (c) to relate the extent of protein modification to that of biological function impairment (such as enzyme inhibition) finally causing the specific health damage. This review describes the role that contemporary mass spectrometry-based approaches employed in the qualitative and quantitative study of protein-electrophile adducts play in the discovery of the (bio)chemical mechanisms of toxic substances and highlights the future directions of research in this field. A particular emphasis is given to the measurement of often high levels of the protein adducts of several industrial and environmental pollutants in unexposed human populations, a phenomenon which highlights the possibility that a number of small organic molecules are generated in the human organism through minor metabolic processes, the imbalance of which may be the cause of "spontaneous" cases of cancer and of other degenerative diseases of still uncharacterized etiology. With all this in mind, it is foreseen that a holistic description of cellular functions will take advantage of new analytical methods based on time-integrated metabolomic measurements of a new biological compartment, the "adductome," aimed at better understanding integrated organism response to environmental and endogenous stressors.
Collapse
Affiliation(s)
- Federico Maria Rubino
- Laboratory for Analytical Toxicology and Metabonomics, Department of Medicine, Surgery and Odontology, Università degli Studi di Milano at Ospedale San Paolo, v. Antonio di Rudinì 8, Milano I-20142, Italy.
| | | | | | | |
Collapse
|
24
|
Hah SS, Henderson PT, Turteltaub KW. Recent advances in biomedical applications of accelerator mass spectrometry. J Biomed Sci 2009; 16:54. [PMID: 19534792 PMCID: PMC2712465 DOI: 10.1186/1423-0127-16-54] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2008] [Accepted: 06/17/2009] [Indexed: 11/13/2022] Open
Abstract
The use of radioisotopes has a long history in biomedical science, and the technique of accelerator mass spectrometry (AMS), an extremely sensitive nuclear physics technique for detection of very low-abundant, stable and long-lived isotopes, has now revolutionized high-sensitivity isotope detection in biomedical research, because it allows the direct determination of the amount of isotope in a sample rather than measuring its decay, and thus the quantitative analysis of the fate of the radiolabeled probes under the given conditions. Since AMS was first used in the early 90's for the analysis of biological samples containing enriched 14C for toxicology and cancer research, the biomedical applications of AMS to date range from in vitro to in vivo studies, including the studies of 1) toxicant and drug metabolism, 2) neuroscience, 3) pharmacokinetics, and 4) nutrition and metabolism of endogenous molecules such as vitamins. In addition, a new drug development concept that relies on the ultrasensitivity of AMS, known as human microdosing, is being used to obtain early human metabolism information of candidate drugs. These various aspects of AMS are reviewed and a perspective on future applications of AMS to biomedical research is provided.
Collapse
Affiliation(s)
- Sang Soo Hah
- Department of Chemistry and Research Institute for Basic Sciences, Kyung Hee University 1 Hoegi-dong, Dongdaemun-gu, Seoul 130-701, Korea.
| | | | | |
Collapse
|
25
|
Abstract
The anti-oestrogen tamoxifen, which is widely used in the treatment of breast cancer and is also approved for the prevention of this disease, causes an increased incidence of endometrial cancer in women. The ability of tamoxifen to induce endometrial tumours and the underlying carcinogenic mechanisms have been a subject of intense interest over the last approximately 20 years. They are central to the assessment of risks versus benefits for the drug, especially in a chemopreventive context. This review outlines the clinical justification for using tamoxifen as a chemopreventive agent and describes the genotoxic mechanisms considered responsible for tamoxifen-induced tumours in rat liver and how these might relate to women. In rat hepatic tissue, tamoxifen is metabolically activated via alpha-hydroxylation and sulphate conjugation to give a reactive species that binds to DNA predominantly at the N(2)-position of guanine, producing pro-mutagenic lesions. Whether tamoxifen-DNA adducts contribute similarly to the development of cancers in women depends on whether they can be formed in human tissues and the type of specific molecular and cellular responses they induce, if present. This review discusses the current data relating to these issues and highlights areas where further research is needed.
Collapse
Affiliation(s)
- Karen Brown
- Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester LE2 7LX, UK.
| |
Collapse
|
26
|
Marsden DA, Jones DJL, Britton RG, Ognibene T, Ubick E, Johnson GE, Farmer PB, Brown K. Dose-response relationships for N7-(2-hydroxyethyl)guanine induced by low-dose [14C]ethylene oxide: evidence for a novel mechanism of endogenous adduct formation. Cancer Res 2009; 69:3052-9. [PMID: 19276345 DOI: 10.1158/0008-5472.can-08-4233] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Ethylene oxide (EO) is widely used in the chemical industry and is also formed in humans through the metabolic oxidation of ethylene, generated during physiologic processes. EO is classified as a human carcinogen and is a direct acting alkylating agent, primarily forming N7-(2-hydroxyethyl)guanine (N7-HEG). To conduct accurate human risk assessments, it is vital to ascertain the relative contribution of endogenously versus exogenously derived DNA damage and identify the sources of background lesions. We have therefore defined in vivo dose-response relationships over a concentration range relevant to human EO exposures using a dual-isotope approach. By combining liquid chromatography-tandem mass spectrometry and high-performance liquid chromatography-accelerator mass spectrometry analysis, both the endogenous and exogenous N7-HEG adducts were quantified in tissues of [(14)C]EO-treated rats. Levels of [(14)C]N7-HEG induced in spleen, liver, and stomach DNA increased in a linear manner from 0.002 to 4 adducts/10(8) nucleotides. More importantly, the extent of damage arising through this route was insignificant compared with the background abundance of N7-HEG naturally present. However, at the two highest doses, [(14)C]EO exposure caused a significant increase in endogenous N7-HEG formation in liver and spleen, suggesting that EO can induce physiologic pathways responsible for ethylene generation in vivo and thereby indirectly promote N7-HEG production. We present evidence for a novel mechanism of adduct formation to explain this phenomenon, involving oxidative stress and 1-aminocyclopropane-1-carboxylic acid as a potential biosynthetic precursor to ethylene in mammalian cells. Based on the proposed pathway, N7-HEG may have potential as a biomarker of cellular oxidative stress.
Collapse
Affiliation(s)
- Debbie A Marsden
- Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, United Kingdom
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Nilgün Çömezoğlu S, Ly VT, Zhang D, Griffith Humphreys W, Bonacorsi SJ, Everett DW, Cohen MB, Gan J, Beumer JH, Beijnen JH, Schellens JH, Lappin G. Biotransformation Profiling of [14C]Ixabepilone in Human Plasma, Urine and Feces Samples Using Accelerator Mass Spectrometry (AMS). Drug Metab Pharmacokinet 2009; 24:511-22. [DOI: 10.2133/dmpk.24.511] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
28
|
Flarakos J, Liberman RG, Tannenbaum SR, Skipper PL. Integration of continuous-flow accelerator mass spectrometry with chromatography and mass-selective detection. Anal Chem 2008; 80:5079-85. [PMID: 18494504 DOI: 10.1021/ac800286g] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Physical combination of an accelerator mass spectrometry (AMS) instrument with a conventional gas chromatograph-mass spectrometer (GC/MS) is described. The resulting hybrid instrument (GC/MS/AMS) was used to monitor mass chromatograms and radiochromatograms simultaneously when (14)C-labeled compounds were injected into the gas chromatograph. Combination of the two instruments was achieved by splitting the column effluent and directing half to the mass spectrometer and half to a flow-through CuO reactor in line with the gas-accepting AMS ion source. The reactor converts compounds in the GC effluent to CO2 as required for function of the ion source. With cholesterol as test compound, the limits of quantitation were 175 pg and 0.00175 dpm injected. The accuracy achieved in analysis of five nonzero calibration standards and three quality control standards, using cholesterol-2,2,3,4,4,6-d6 as injection standard, was 100 +/- 11.8% with selected ion monitoring and 100 +/- 16% for radiochromatography. Respective values for interday precision were 1.0-3.2 and 22-32%. Application of GC/MS/AMS to a current topic of interest was demonstrated in a model metabolomic study in which cultured primary hepatocytes were given [(14)C]glucose and organic acids excreted into the culture medium were analyzed.
Collapse
Affiliation(s)
- Jimmy Flarakos
- Biological Engineering Department, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | | | | | | |
Collapse
|
29
|
Baillie TA. Metabolism and Toxicity of Drugs. Two Decades of Progress in Industrial Drug Metabolism. Chem Res Toxicol 2007; 21:129-37. [DOI: 10.1021/tx7002273] [Citation(s) in RCA: 158] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Affiliation(s)
- Thomas A. Baillie
- Merck Research Laboratories, Department of Drug Metabolism and Pharmacokinetics WP75B-330, Sumneytown Pike, West Point, Pennsylvania 19486-0004
| |
Collapse
|
30
|
Rubakhin SS, Sweedler JV. Transparent triethylamine-containing MALDI matrices. Isr J Chem 2007. [DOI: 10.1560/ijc.47.2.185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
31
|
Godin JP, Fay LB, Hopfgartner G. Liquid chromatography combined with mass spectrometry for 13C isotopic analysis in life science research. MASS SPECTROMETRY REVIEWS 2007; 26:751-74. [PMID: 17853432 DOI: 10.1002/mas.20149] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/17/2023]
Abstract
Among the different disciplines covered by mass spectrometry, measurement of (13)C/(12)C isotopic ratio crosses a large section of disciplines from a tool revealing the origin of compounds to more recent approaches such as metabolomics and proteomics. Isotope ratio mass spectrometry (IRMS) and molecular mass spectrometry (MS) are the two most mature techniques for (13)C isotopic analysis of compounds, respectively, for high and low-isotopic precision. For the sample introduction, the coupling of gas chromatography (GC) to either IRMS or MS is state of the art technique for targeted isotopic analysis of volatile analytes. However, liquid chromatography (LC) also needs to be considered as a tool for the sample introduction into IRMS or MS for (13)C isotopic analyses of non-volatile analytes at natural abundance as well as for (13)C-labeled compounds. This review presents the past and the current processes used to perform (13)C isotopic analysis in combination with LC. It gives particular attention to the combination of LC with IRMS which started in the 1990's with the moving wire transport, then subsequently moved to the chemical reaction interface (CRI) and was made commercially available in 2004 with the wet chemical oxidation interface (LC-IRMS). The LC-IRMS method development is also discussed in this review, including the possible approaches for increasing selectivity and efficiency, for example, using a 100% aqueous mobile phase for the LC separation. In addition, applications for measuring (13)C isotopic enrichments using atmospheric pressure LC-MS instruments with a quadrupole, a time-of-flight, and an ion trap analyzer are also discussed as well as a LC-ICPMS using a prototype instrument with two quadrupoles.
Collapse
Affiliation(s)
- Jean-Philippe Godin
- Nestlé Research Center, Nestec Ltd, Vers chez les blanc, P.O. BOX 44, CH-1000 Lausanne 26, Switzerland.
| | | | | |
Collapse
|
32
|
Brown K, Tompkins EM, Boocock DJ, Martin EA, Farmer PB, Turteltaub KW, Ubick E, Hemingway D, Horner-Glister E, White INH. Tamoxifen forms DNA adducts in human colon after administration of a single [14C]-labeled therapeutic dose. Cancer Res 2007; 67:6995-7002. [PMID: 17638912 DOI: 10.1158/0008-5472.can-07-0913] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Tamoxifen is widely prescribed for the treatment of breast cancer and is also licensed in the United States for the prevention of this disease. However, tamoxifen therapy is associated with an increased occurrence of endometrial cancer in women, and there is also evidence that it may elevate the risk of colorectal cancer. The underlying mechanisms responsible for tamoxifen-induced carcinogenesis in women have not yet been elucidated, but much interest has focused on the role of DNA adduct formation. We investigated the propensity of tamoxifen to bind irreversibly to colorectal DNA when given to 10 women as a single [(14)C]-labeled therapeutic (20 mg) dose, approximately 18 h before undergoing colon resections. Using the sensitive technique of accelerator mass spectrometry, coupled with high-performance liquid chromatography separation of enzymatically digested DNA, a peak corresponding to authentic dG-N(2)-tamoxifen adduct was detected in samples from three patients, at levels ranging from 1 to 7 adducts/10(9) nucleotides. No [(14)C]-radiolabel associated with tamoxifen or its major metabolites was detected. The presence of detectable CYP3A4 protein in all colon samples suggests that this tissue has the potential to activate tamoxifen to alpha-hydroxytamoxifen, in addition to that occurring in the systemic circulation, and direct interaction of this metabolite with DNA could account for the binding observed. Although the level of tamoxifen-induced damage displayed a degree of interindividual variability, when present, it was approximately 10 to 100 times higher than that reported for other suspect human colon carcinogens such as 2-amino-1-methyl-6-phenyimidazo[4,5-b]pyridine. These findings provide a mechanistic basis through which tamoxifen could increase the incidence of colon cancers in women.
Collapse
Affiliation(s)
- Karen Brown
- Cancer Biomarkers and Prevention Group, Reproductive Sciences, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, United Kingdom.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Sturla SJ. DNA adduct profiles: chemical approaches to addressing the biological impact of DNA damage from small molecules. Curr Opin Chem Biol 2007; 11:293-9. [PMID: 17574899 DOI: 10.1016/j.cbpa.2007.05.021] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2007] [Accepted: 05/29/2007] [Indexed: 10/23/2022]
Abstract
Diverse small molecules alkylate DNA and form covalently linked adducts that can influence crucial biological processes, contributing to toxicity and mutation. Understanding the chemical reactivity dictating DNA alkylation and interactions of adducts with biological pathways can impact disease prevention and treatment. The ambident reactivity of DNA-alkylating small molecules, and of DNA itself, often results in formation of multiple adducts. Determining which structures impart biological responses is important for understanding the underlying relationships between small-molecule structure and biology. With application of sensitive and structure-specific experimental and analytical methodology, such as heteronuclear NMR spectroscopy and mass spectrometry, there are increasing numbers of studies that evaluate DNA alkylation from the perspective of resulting adduct profiles. DNA adduct profiles have been examined for both exogenous and endogenous reactive small molecules. Examples of recent findings are in the areas of tobacco-specific carcinogens, lipid peroxidation products, environmental and dietary chlorophenols, and natural-product-derived antitumor therapies. As more profile data are obtained, correlations with biological impact are being observed that would not be identified by a simplified single agent/single adduct approach.
Collapse
Affiliation(s)
- Shana J Sturla
- Department of Medicinal Chemistry and The Cancer Center, University of Minnesota, 308 Harvard Street SE, Minneapolis, MN 55455, USA.
| |
Collapse
|
34
|
Zencak Z, Reddy CM, Teuten EL, Xu L, McNichol AP, Gustafsson O. Evaluation of Gas Chromatographic Isotope Fractionation and Process Contamination by Carbon in Compound-Specific Radiocarbon Analysis. Anal Chem 2007; 79:2042-9. [PMID: 17256874 DOI: 10.1021/ac061821a] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The relevance of both modern and fossil carbon contamination as well as isotope fractionation during preparative gas chromatography for compound-specific radiocarbon analysis (CSRA) was evaluated. Two independent laboratories investigated the influence of modern carbon contamination in the sample cleanup procedure and preparative capillary gas chromatography (pcGC) of a radiocarbon-dead 3,3',4,4',5,5'-hexachlorobiphenyl (PCB 169) reference. The isolated samples were analyzed for their 14C/12C ratio by accelerator mass spectrometry. Sample Delta14C values of -996 +/- 20 and -985 +/- 20 per thousand agreed with a Delta14C of -995 +/- 20 per thousand for the unprocessed PCB 169, suggesting that no significant contamination by nonfossil carbon was introduced during the sample preparation process at either laboratory. A reference compound containing a modern 14C/12C ratio (vanillin) was employed to evaluate process contamination from fossil C. No negative bias due to fossil C was observed (sample Delta14C value of 165 +/- 20 per thousand agreed with Delta14C of 155 +/- 12 per thousand for the unprocessed vanillin). The extent of isotopic fractionation that can be induced during pcGC was evaluated by partially collecting the vanillin model compound of modern 14C/12C abundance. A significant change in the delta13C and delta14C values was observed when only parts of the eluting peak were collected (delta13C values ranged from -15.75 to -49.91 per thousand and delta14C values from -82.4 to +4.71 per thousand). Delta14C values, which are normalized to a delta13C of -25 per thousand, did not deviate significantly (-58.9 to -5.8 per thousand, considering the uncertainty of approximately +/-20 per thousand). This means that normalization of radiocarbon results to a delta13C of -25 per thousand, normally performed to remove effects of environmental isotope fractionation on 14C-based age determinations, also cor-rects sufficiently for putative isotopic fractionation that may occur during pcGC isolation of individual compounds for CSRA.
Collapse
Affiliation(s)
- Zdenek Zencak
- Department of Applied Environmental Science (ITM), Stockholm University, 10691 Stockholm, Sweden
| | | | | | | | | | | |
Collapse
|
35
|
Gilbert TW, Stewart-Akers AM, Badylak SF. A quantitative method for evaluating the degradation of biologic scaffold materials. Biomaterials 2007; 28:147-50. [PMID: 16949150 DOI: 10.1016/j.biomaterials.2006.08.022] [Citation(s) in RCA: 95] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2006] [Accepted: 08/11/2006] [Indexed: 11/26/2022]
Abstract
Scaffolds derived from naturally occurring extracellular matrix (ECM) have found extensive use in the fields of tissue engineering and regenerative medicine. Many of these scaffolds are designed to degrade rapidly as they are replaced by new host tissue. Other scaffolds are chemically crosslinked to slow the rate of degradation or add strength to the scaffold. Commercially available ECM scaffolds have considerable variability with regards to tissue origin and methods of processing, and little is known about their rate of degradation and the fate of their degradation products. A novel method is described herein to integrally label ECM with a radioactive isotope ((14)C). It was found that a number of tissues are efficiently labeled, including heart, liver, trachea, pancreas, small intestine, and urinary bladder tissue. Of the tissues analyzed, only spleen was not found to contain detectable levels of (14)C. The technique is extremely sensitive, accurate, and safe, but requires access to accelerator mass spectrometry, and is expensive and time consuming. This model represents the first described quantitative method to determine the rate of degradation for an ECM scaffold and to track the fate of the degradation products.
Collapse
Affiliation(s)
- Thomas W Gilbert
- McGowan Institute for Regenerative Medicine, University of Pittsburgh, 100 Technology Drive, Suite 200, Pittsburgh, PA 15219, USA
| | | | | |
Collapse
|
36
|
Skipper PL, Trudel LJ, Kensler TW, Groopman JD, Egner PA, Liberman RG, Wogan GN, Tannenbaum SR. DNA adduct formation by 2,6-dimethyl-, 3,5-dimethyl-, and 3-ethylaniline in vivo in mice. Chem Res Toxicol 2006; 19:1086-90. [PMID: 16918249 DOI: 10.1021/tx060082q] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Aromatic amines such as 2-naphthylamine and 4-aminobiphenyl are established human bladder carcinogens. Experimental evidence for carcinogenicity of monocylic aromatic amines is limited mostly to other organs, but a recent epidemiologic study of bladder cancer found that 2,6-dimethyl- (2,6-DMA), 3,5-dimethyl- (3,5-DMA), and 3-ethylaniline (3-EA) may play a significant role in the etiology of this disease in man. The present work was undertaken to test whether a genotoxic mechanism can account for the presumptive activity of 2,6-DMA, 3,5-DMA, and 3-EA by quantifying the binding of these compounds to DNA in vivo. Each of these three [(14)C]alkylanilines was administered at approximately 100 microg/kg to C57BL/6 mice, which were subsequently sacrificed 2, 4, 8, 16, and 24 h post-dosing. Bladder, colon, kidney, liver, lung, and pancreas were harvested from each animal, and DNA was isolated from each tissue. Adduct levels were determined by quantifying bound isotope using accelerator mass spectrometry. Adducts were detectable in the bladder and liver DNA samples from every animal at every time point at levels that ranged from 3 per 10(9) to 1.5 per 10(7) nucleotides. Adduct levels were highest in animals given 3,5-DMA and lowest in those given 3-EA. Levels in both bladder and liver declined by severalfold over the course of the experiment. Adducts were detected less frequently in the other four tissues. Taken together, the results strongly suggest that these three alkylanilines are metabolized in vivo to electrophilic intermediates that covalently bind to DNA and that adducts are formed in the DNA of bladder, which is a putative target organ for these alkylanilines.
Collapse
Affiliation(s)
- Paul L Skipper
- Biological Engineering Division, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA. skipper@ mit.edu
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Tompkins EM, Farmer PB, Lamb JH, Jukes R, Dingley K, Ubick E, Turteltaub KW, Martin EA, Brown K. A novel 14C-postlabeling assay using accelerator mass spectrometry for the detection of O6-methyldeoxy-guanosine adducts. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2006; 20:883-91. [PMID: 16470516 DOI: 10.1002/rcm.2370] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
Accelerator mass spectrometry (AMS) is currently one of the most sensitive methods available for the trace detection of DNA adducts and is particularly valuable for measuring adducts in humans or animal models. However, the standard approach requires administration of a radiolabeled compound. As an alternative, we have developed a preliminary 14C-postlabeling assay for detection of the highly mutagenic O6-methyldeoxyguanosine (O6-MedG), by AMS. Procedures were developed for derivatising O6-MedG using unlabeled acetic anhydride. Using conventional liquid chromatography/mass spectrometry (LC/MS) analysis, the limit of detection (LOD) for the major product, triacetylated O6-MedG, was 10 fmol. On reaction of O6-MedG with 14C-acetic anhydride, using a specially designed enclosed system, the predominant product was 14C-di-acetyl O6-MedG. This change in reaction profile was due to a modification of the reaction procedure, introduced as a necessary safety precaution. The LOD for 14C-di-acetyl O6-MedG by AMS was determined as 79 amol, approximately 18,000-fold lower than that achievable by liquid scintillation counting (LSC). Although the assay has so far only been carried out with labeled standards, the degree of sensitivity obtained illustrates the potential of this assay for measuring O6-MedG levels in humans.
Collapse
Affiliation(s)
- Elaine M Tompkins
- Cancer Biomarkers and Prevention Group, Department of Cancer Studies and Molecular Medicine, The Biocentre, University of Leicester, University Road, Leicester LE1 7RH, UK
| | | | | | | | | | | | | | | | | |
Collapse
|